Israel - Tiếng Do Thái - Ministry of Health

taro pharmaceutical industries ltd - warfarin sodium - טבליה - warfarin sodium 10 mg - warfarin - warfarin - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. coumadin is indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Israel - Tiếng Do Thái - Ministry of Health

pharmalogic ltd - heparin sodium - תמיסה להזרקה\אינפוזיה - heparin sodium 5000 iu/ml - heparin - heparin - treatment of thrombo-embolic disorders as deep vein thrombosis, acute arterial embolism or thrombosis, thrombophlebitis, pulmonary embolism , fat embolism. prophylaxis of deep vein thrombosis and thromboembolic events.

Israel - Tiếng Do Thái - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 5000 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism.unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Israel - Tiếng Do Thái - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 2500 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Israel - Tiếng Do Thái - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - תמיסה להזרקה - dalteparin sodium 2500 iu/ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.

Israel - Tiếng Do Thái - Ministry of Health

sanofi israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - enoxaparin sodium is an anti-coagulant. at dosesof 20 mg and 40 mg it is indicated for: - prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. at dosege of 40 mg the indications are: - prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - heart failure (hyha class iii or iv) - acute respiratory failure - episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. at high doses of 60, 80 ,100 mg clexan is indicated for: -treatment of deep vein thrombosis (dvt). - treatment of unstable angina and non-q-wave myocardial infaction administered concurrently with aspirin. - treatment of pulmonary embolism.treatment of acute st- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

Israel - Tiếng Do Thái - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium - תמיסה להזרקה - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin - for treatment of deep vein thrombosis (dvt) once daily. treatment of pulmonary embolism once daily.

Israel - Tiếng Do Thái - Ministry of Health

salomon,levin & elstein ltd - epoprostenol as sodium 1.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

Israel - Tiếng Do Thái - Ministry of Health

salomon,levin & elstein ltd - epoprostenol as sodium 0.5 mg - powder and solvent for solution for infusion - epoprostenol - epoprostenol teva is indicated for the long-term intravenous treatment of primary arterial pulmonary hypertension and arterial pulmonary hypertension associated with the scleroderma spectrum of disease in nyha class iii and class iv patients who do not respond to conventional therapy.

Israel - Tiếng Do Thái - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - תמיסה להזרקה - treprostinil as sodium 5 mg/ml - treprostinil - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.